More money is spent advertising alcohol than any other product. For some, it like gambling and cigarettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease. According to a new report by visiongain - Anti-addiction Therapies, 2006-2011 - society is crying out for solutions. Which pharmaceutical companies are now aiming to be that cure? This report will tell you.

Doctors and concerned specialists have long maintained a behavioural- based approach to treating addiction is the most effective treatment programme. Suggested pharmaceutical solutions simply did not work. That is it seems...until now. Two leading pharmaceutical companies have developed novel drugs that could revolutionise the treatment of obesity and nicotine addiction. And what is more, those drugs could save health authorities millions of dollars. With the pharmaceutical industry anxiously seeking the next blockbuster product, it is hardly surprising that Chantix and Acomplia are generating so much interest. Are these drugs set to shift the focus of the pharmaceutical industry? Find out today.

Will these drugs really make much of a difference for such complex disorders? Is this not just the industry wary of decline seizing an opportunity to make money? Visiongain's report - Anti-addiction Therapies, 2006-2011 - assesses the currently available drugs, analysing which pipeline drugs appear to fit unmet needs best. This report also examines which pharmaceutical companies are likely to be market leaders by 2011.

Pfizer's Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis' Acomplia might provide not only much needed effective relief to thousands of addicts, but could also help develop and drive a market as Viagra did for erectile dysfunction. Markets that are currently worth $1 billion could multiply several-fold within the foreseeable future.

"If Chantix and Acomplia prove to be as effective, but with the minimal side effect profiles that Pfizer and Sanofi-Aventis claim, then we could see significant development in these treatment markets," commented visiongain market analyst and author of this latest report, Tristan Heath. This optimism is based upon the increasing incidence of obesity throughout the developed world and the stated wish of 70% of smokers to quit tobacco. Health authorities throughout the developed world have placed these health issues as top priorities. This is a potential market you cannot afford to ignore. Imagine the potential success your company could aachieve through being informed of this market now.

Treatment can be tailored to the individual and typically involve a combination of drug and behavioural therapy. Treatment of drug addiction is usually a long, multi-stage process. Encouragingly, modern drug- dependency treatment regimes are generally believed to be effective, with 40-70% of patients successfully recovering from their addiction. Can that same success be repeated in other addictions. Find out now by simply placing your order for this business critical report.

What is in the report?

Statistics of addiction, including potential patient populations and the economic burden of addiction.
Drug addiction - Heroin and cocaine addiction treatments, including the development of vaccinations for cocaine addiction.
Alcohol addiction - A review of the new products for the treatment of alcohol addiction, largely those that have been indicated for the treatment of depression or opioid addiction.
Smoking addiction - Potentially a huge market. Many health authorities have placed smoking as a priority. Pfizer have recently launched Chantix, which is likely to be the first specific treatment for smoking that is an alternative to the nicotine replacement.
Gambling addiction - A market that is more potential than current reality. It faces difficulties in both developing effective treatments and overcoming cultural perception that gambling is not something that should necessarily be treated by a pharmaceutical.
Obesity treatment - Potentially the largest market. The prevalence of obesity is increasing, with Sanofi-Aventis having recently launched Acomplia.
Pipeline products - The interest in the addiction markets stems from the potentially large patient populations and also the large number of products in the pipeline.
World market by country region for the specific treatment markets. Specific drivers and restraints for the addiction treatment markets are considered.
Unique research and primary information unavailable elsewhere

Why you must by this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the addiction treatment markets hold promise, particularly for the development of products for nicotine addiction and the treatment of obesity. This report analyses the current situation in the market and assesses the potential of the products that are currently in the development pipeline. A comprehensive analysis of the addiction treatment market from 2006-2011 outlines the potential of the market. Visiongain expects to see the development of at least two multi-billion dollar markets. You and your company should be part of this market, and you could be by placing your order immediately.

Unique benefits to you when you order this report:

Full searchable report when you buy the company or corporate editions
Immediate access through our exclusive Reading Room
You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

1. Executive Summary

2. Introduction

2.1 Drug Addiction/Abuse/Dependency Definitions
2.2 The Development of Drugs Specifically for Treating Addiction
2.3 Maintenance Treatment is Controversial
2.4 Objectives, Methodology and Scope

3. The Physiology and Psychology of Addiction

3.1. Addiction Affects Many Areas of the Brain
3.2. Dopamine is Key
3.3. GABA Imbalance Incites Craving
3.4. The Psychology of Addiction

4. Regional Prevalence of Addiction

4.1 The Economic Cost of Addiction
4.2 Drug Dependency Low, But Severe Hazard
4.3 Alcohol Dependency Increasing Despite Health Consequences
4.4 Smoking Prevalence Causes Highest Fatality Rates From Dependency
5.5 Associated Problems Increase With Gambling Increase

5. Drug Addiction

5.1 Heroin - The Most Serious of all Addictions?
5.2 What Happens When Heroin is Taken?
- 5.2.1 Withdrawal Symptoms
5.3 Drug Addiction Treatments
- 5.3.1 Opioid Addiction Has Well Tried Treatments
5.4 Opioid Dependence Treatment Regimes
5.5 Naltrexone Implants Remain Expensive
5.6 Cocaine Addiction Looks To Future Success
5.7 Cocaine Treatment - A Vaccine Available Soon?
- 5.7.1 Drugs to reduce symptoms of cocaine abstinence or craving
5.8 Market Outlook For Drug Addiction Treatments
5.8.1 Cocaine Addiction Treatments Hold Greatest Promise

6. Alcohol Addiction

6.1 The Effects and Problems Associated With Alcohol
6.2 Alcohol dependency tests
6.3 Alcohol Addiction Treatments
- 6.3.1 Antabuse - Available Since 1948
- 6.3.2 Naltrexone Now Available in Injectable Form
6.4 Campral Offers Another Mode of Action for Alcohol Dependency Treatment
6.5 Most Recent Alcohol Dependency Drug From J&J
6.6 Serotonergic Agents Show Limited Usefulness
6.7 Drug treatment for related disorders
6.8 Market Outlook For Alcohol Dependency Treatments

7. Smoking Addiction

7.1 How to assess the level of nicotine addiction?
7.2 Smoking Addiction Treatments
- 7.2.1 Chantix is the Latest Anti-smoking Treatment
- 7.2.2 NRT Dominates Smoking Treatment Therapies
- 7.2.3 Zyban Provides Effective Treatment
7.3 Beneficial Effects Are Quickly Noticeable
7.4 Withdrawal Effects Are Also Quickly Noticeable
7.5 Market Outlook for Nicotine Dependency Treatments
8. Gambling Addiction
8.1 Gambling Addiction Treatments
- 8.1.1 Opioid Antagonists (OA)
- 8.1.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 8.1.3 Mood Stabilisers
- 8.1.4 Other Pharmaceutical Treatment Options for Gambling Treatment
8.2 Market Outlook for Gambling Addiction Treatments

9. Obesity and Food Addiction

9.1 Obesity and Food Addiction Treatments
9.2 Will Acomplia Accomplish More?
9.3 Other Opportunities For Obesity Treatment
9.3.1 Hormone Treatment Greeted With Optimism
9.4 Market Outlook for Obesity Treatments

10. World Market by Region

10.1 Drivers and Restraints
10.2 The US Market Presents Considerable Opportunities
10.3 The Japanese Market May Accept Treatments on a Limited Scale
10.4 US Market Is Surprisingly Undeveloped For Addiction Treatments

11. Unmet Needs in Addiction Treatments

11.1 Pipeline Products for the Treatment of Drug Addiction
11.2 Fulcrum's Link With Celtic Could Produce Novel Addiction Therapies
11.3 Genetic Link Between Disorders Inspires Further Research
11.4 Drug addiction
11.4.1 Opioid Addiction
11.4.2 Cocaine Addiction
11.5 Alcohol Addiction
11.6 Smoking Addiction
11.7 Grants From the US NIDA Used to Develop Nicotine Vaccination
11.8 Gambling Addiction
11.9 Obesity Food Addiction - Huge Interest in Potentially Lucrative Market

12. Sanofi-Aventis: A Review

12.1 The Takeover of Aventis By Sanofi was Aggressive
12.2 Sanofi-Aventis Continues to Expand

13. Conclusion

Tables

Table 5.1 A Comparison of the Heroin Dependency Treatment Options
Table 7.1 Leading Available NRT Products
Table 7.2 Beneficial Effects of Smoking Cessation
Table 7.3 The Duration of Smoking Withdrawal Effects
Table 7.4 World Revenue ($m) for Chantix, 2005-2011
Table 9.1 World Revenue ($m) for Acomplia, 2005-2011
Table 10.1 Leading Drugs For The Addiction Treatment Markets
Table 10.2 World Revenue ($m) and Growth Rate (%) of the Obesity Treatment Market, by Region, 2005
Table 10.3 World Revenue ($m) and Growth Rate (%) of the Nicotine Addiction Treatment Market, by Region, 2005
Table 10.4 World Revenue ($m) and Growth Rate (%) of the Alcohol Dependency Treatment Market, by Region, 2005
Table 11.1 Pipeline Products For Anti-Drug Addiction Treatments
Table 11.2 Pipeline Products for Cocaine Addiction Treatment
Table 11.3 Pipeline Products for Alcohol Dependency Treatment
Table 11.4 Pipeline Products for Obesity Treatment
Table 11.5 Pipeline Products for Gambling Addiction
Table 11.6 Selected Key Pipeline Products For Obesity Treatment

Figures

Figure 1.1 World Revenue ($m) for Acomplia, 2005-2011
Figure 6.1 Alcohol Consumption in Young Adults (18-29 years)
Figure 6.2 Percentage of Children Aged 15-16 Drunk Over 20 Times in Lifetime
Figure 7.1 World Revenue ($m) for Chantix, 2005-2011
Figure 9.1 World Revenue ($m) for Acomplia, 2005-2011
Figure 10.1 Market Share (%) for Obesity Treatments by Region, 2005
Figure 10.2 Market Share (%) for Nicotine Addiction Treatments by Region, 2005
Figure 10.3 Market Share (%) for Nicotine Addiction Treatments by Region, 2005

Organisations Listed

Abbott Laboratories
Aktiv-Dry
Alizyme
Alkermes
Alpharma
Amgen
Amylin
Arena
Britannia Pharmaceuticals
BioTie Therapies
British American Tobacco
Celtic Pharma
Cephalon
Cetilistat
Cytos Biotech
DrugAbuse Sciences
Eisai
Forest
Fujisawa
Fulcrum Pharma
GSK
Hokuriku Seiyaku
Hythiam
INSERM
Johnson & Johnson
Lipha Pharmaceuticals
Merck
Merck KGaA
Metabolic
Nabi Pharmaceuticals
Nastech
New River Pharmaceuticals
Nippon Shinyaku
Novartis
Peptimmune genzyme
Pfizer
Philip Morris
Phytopharm
Pliva
Reckitt Benckiser
Roche
Sanofi-Aventis
Schering-Plough
Shionogi
Shire
Somaxon
Titan Pharmaceuticals
Unilever
Valera
Vernalis
Xenova
7TM Pharma

Introduction
Related Reports

User Guide About Us Policies Site Map

Int'l: +1-860-674-8796 US: +1-866-353-3335 (Toll Free) | EU: +32-2-535-7543

Anti-addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra?

Introduction

Abstract